HDAC inhibitor CS014 inhibits platelet activity, small and large vessel thrombosis while maintaining haemostasis in a dose-dependent manner

Back

ESC Professional Premium Access

HDAC inhibitor CS014 inhibits platelet activity, small and large vessel thrombosis while maintaining haemostasis in a dose-dependent manner

Session: Current and novel antiplatelet therapy in cardiovascular disease

Topic: Antiplatelet Drugs

Speaker: Professor M. Holinstat (Ann Arbor, US)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Professor Michael Holinstat

University of Michigan, Ann Arbor (United States of America)

1 follower

5 more presentations in this session

Superiority of CS585 as a selective prostacyclin receptor agonist in prevention of thrombosis

Speaker: Ms L. Stanger (Ann Arbor, US)

Acetylsalicylic acid challenge or desensitization in sensitive patients with cardiovascular disease

Speaker: Doctor M. Galli (Rome, IT)

Variability of the antithrombotic effect of acetylsalicylic acid with the administration of different dosages: reality or myth?

Speaker: Doctor J. Lima Lopes (Amadora, PT)

Antiplatelet effect of acetylsalicylic acid in patients early after cardiac valve surgery: comparative investigation of the impairment of platelet inhibition by dipyrone versus acetaminophen

Speaker: Professor D. Trenk (Bad Krozingen, DE)

CYP2C19 genotype prevalence and association with recurrent myocardial infarction in British-South Asians treated with clopidogrel

Speaker: Doctor E. Magavern (London, GB)

Access the full session

Current and novel antiplatelet therapy in cardiovascular disease

Speakers: Professor M. Holinstat, Ms L. Stanger, Doctor M. Galli, Doctor J. Lima Lopes, Professor D. Trenk...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources